GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CEN Biotech Inc (OTCPK:CENBF) » Definitions » ROC (Joel Greenblatt) %

CEN Biotech (CEN Biotech) ROC (Joel Greenblatt) % : -1,071.59% (As of Mar. 2023)


View and export this data going back to 2016. Start your Free Trial

What is CEN Biotech ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CEN Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -1,071.59%.

The historical rank and industry rank for CEN Biotech's ROC (Joel Greenblatt) % or its related term are showing as below:

CENBF's ROC (Joel Greenblatt) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.15
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

CEN Biotech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


CEN Biotech ROC (Joel Greenblatt) % Historical Data

The historical data trend for CEN Biotech's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEN Biotech ROC (Joel Greenblatt) % Chart

CEN Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -578.04 -862.87 4,755.17 -7,666.53 -662.47

CEN Biotech Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -240.53 -601.00 -818.13 -1,149.51 -1,071.59

Competitive Comparison of CEN Biotech's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, CEN Biotech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEN Biotech's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CEN Biotech's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where CEN Biotech's ROC (Joel Greenblatt) % falls into.



CEN Biotech ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.109 + 0 + 0.026) - (4.923 + 0 + 0)
=-4.788

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.102 + 0 + 0.026) - (4.936 + 0 + -0.00099999999999945)
=-4.807

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of CEN Biotech for the quarter that ended in Mar. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Mar. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.452/( ( (0.145 + max(-4.788, 0)) + (0.126 + max(-4.807, 0)) )/ 2 )
=-1.452/( ( 0.145 + 0.126 )/ 2 )
=-1.452/0.1355
=-1,071.59 %

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CEN Biotech  (OTCPK:CENBF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


CEN Biotech ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of CEN Biotech's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


CEN Biotech (CEN Biotech) Business Description

Traded in Other Exchanges
N/A
Address
3295 Quality Way, Suite 300, Windsor, ON, CAN, N8T 3R9
Website
CEN Biotech Inc is an early-stage Canadian biopharmaceutical company. The Company grows, sells, and delivers pharmaceutical-grade medical marijuana to patients.
Executives
Lawrence Lehoux director, officer: Chief Technology Officer 11879 SOLOMAN ST, WINDSOR A6 N8P 1P1
Jeffery Allen Thomas director 23772 WEST ROAD #152, BROWNSTOWN TOWNSHIP MI 48183
Rick Leigh Purdy director 9 ELAINE STREET, ST. ALBERT A0 T8N7R6
Usamakh Saadikh director 3 DRUDBGY NARODOV SQUARE, KYIV 2H 04210
Joseph A. Byrne director, officer: Chief Executive Officer 6 CAMERON SIDE ROAD EAST, ESSEX A6 N8M 2X5
Alex Tarrabain director 18908 89 AVENUE, EDMONTON A0 T5T 6B7
Donald Strilchuck director 352 RIDEAU PL, TECUMSEH A6 N8N 3N9
Richard Boswell director, 10 percent owner, officer: CFO Senior Executive VP 2408 EASTERN AVE., ROCHESTER HILLS MI 48307
Ameen Ferris director 30 AYRSHIRE COURT, BRAMPTON A6 L6Z 0G6
Brian Payne director, officer: Vice President 1027 HUNTINGTON BLVD, BELLE RIVER A6 N0R 1A0
Aubrey De Lavenu Harold Andre director APT 627 VALE DO LOBO, ALMANCIL S1 8135-034
Bahige B. Chaaban director, 10 percent owner, officer: Chief Executive Officer 888 OLD TECUMSAH RD., BELLE RIVER A6 N0R 1A0

CEN Biotech (CEN Biotech) Headlines